As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - ...
What Happened? Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) jumped 19.8% in the morning session ...
Charles Schwab Investment Management Inc. cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 0.5% in the fourth quarter, according to its most recent 13F filing with the ...
Lantheus Holdings, Inc.'s stock soars 55%, fueled by Pylarify and strategic acquisitions in Alzheimer's and oncology. Click ...
To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...
Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.
Lantheus Holdings saw an 18.83% increase in its share price over the past week, driven by recent corporate updates and market trends. The company announced its 2024 earnings, reporting a sales ...
Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 ...
Reports Q4 revenue $391.1M, consensus $376.18M. “2024 was a groundbreaking year for Lantheus (LNTH), as our radiodiagnostic, PYLARIFY, reached ...
Lantheus Holdings shares rose after its adjusted earnings for the fourth quarter and 2025 outlook estimates were higher than expected. The stock climbed 20%, to $96.36. The stock has gained about half ...
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) jumped 19.8% in the morning session after the company delivered strong fourth-quarter 2024 results, with revenue and earnings ...
Explore the exciting world of Lantheus Holdings (NASDAQ: LNTH) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...